These investigators compared criteria from the two commonly used pathologic risk classification systems for endometrial carcinoma, assessed their concordance with molecular subtypes, and evaluated associations with patient outcomes.
Findings suggest that early interventions targeting potential causes might reduce risk for endometrial cancer in obese women.
The WID-qEC endometrial cancer test is a 3-marker molecular test that uses self-collected samples, allowing healthy patients to avoid invasive screening methods.
These researchers compared intensive and minimal follow-up and found that intensive follow-up for patients treated for endometrial cancer does not improve overall survival, even among higher risk patients.
Results from a recent phase 1/2 prospective trial showed that stereotactic pelvic adjuvant radiation therapy for uterine cancer is well-tolerated and produced acceptable quality-of-life scores.
A risk stratification scheme for endometrial cancer based solely on immunohistochemistry appears to provide a path to precision care.
Healthcare practitioners should consider screening for genetic mutations such as Lynch syndrome (LS) in all patients with endometrial cancer (EC) or colorectal cancer—an important step that could lead to higher detection rates and better treatment options.
Lower levels of mismatch repair (MMR) proteins can predict worse outcomes in this set of early-stage patients treated with vaginal brachytherapy, according to the results of a Boston-based study. That said, what should be done about it?
By incorporating clinicopathological and molecular factors, researchers can more accurately categorize tumors and better identify patients who would benefit most from adjuvant therapy.